본문 바로가기
KCI 등재

패혈증 유발 파종성 혈관내 응고 환자에서 AntithrombinⅢ 보충의 임상적 효과 분석

Analysis of Clinical Effects of AntithrombinⅢ Supplementation Therapy in Patients with Sepsis-induced Disseminated Intravascular Coagulation

병원약사회지
약어 : JKSHP
2019 vol.36, no.2, pp.232 - 243
DOI : 10.32429/jkshp.2019.36.2.006
발행기관 : 한국병원약사회
연구분야 : 약학
Copyright © 한국병원약사회
박주연 1 ,  정선미 2 ,  오명현 3 ,  김재송 4 ,  손은선 5

1연세대학교의료원 세브란스병원 약무국

2연세대학교의료원 세브란스병원 약무국

3연세대학교의료원 세브란스병원 약무국

4연세대학교의료원 세브란스병원 약무국

5연세대학교의료원 세브란스병원 약무국

인용한 논문 수 :   -  
156 회 열람

Background : A recent research study published in Japan showed the clinical effects of ATⅢ supplementation therapy in patients with sepsis-induced disseminated intravascular coagulation (DIC). The study found that in-hospital mortality decreased only in the group with ATⅢ activation of 43% or less (HR: 0.603, P=0.045). Based on that study, it would be needed to verify a domestic application standard, starting a supplementation therapy at 70% or less of ATⅢ activity. Hence, this study conducted a retrospective analysis of clinical effects according to ATⅢ activation and suggested the need for a new application standard. Methods : Data collected from the electronic medical record were divided into two groups based on 43% ATⅢ activation and the data were analyzed for differences in prothrombin time (PT) and platelet improvement, PT and platelet variation, and 28-day mortality. Results : In 76 sepsis-induced DIC patients who were injected with ATⅢ from January 2015 to December 2017, 35 patients (46.05%) had an ATⅢ activation of 43% or less and 41 (53.95%) were over 43 percent. The number of patients who had PT improvement after ATⅢ supplementation therapy was 16 (45.7%) in the 43% or less ATIII group and 12 (29.3%) in the 43% group (P=0.138). Three patients (8.6%) had platelet improvement in the 43% or less group and three (7.3%) had platelet improvement in the 43% ATIII group (P=1.000). The PT variation was -4.94±7.65 and -3.38±4.89 in the 43% or less and 43% ATIII groups, respectively (P=0.286). The platelet variation was 11.47±30.7 and 6.31±31.86 in the 43% or less and 43% ATIII groups, respectively (P=0.478). The 28-day mortality was 48.6% in the 43% or less ATIII group and 41.5% in the 43% group (P=0.534). Conclusions : As a result of comparing patients exceeding 43% ATⅢ activation with those below 43%, the frequency of PT improvement and the mean of PT variation showed that the patients with 43% ATⅢ activation or less had a tendency toward improvement on a numerical basis. Accordingly, large-scale, multi-center studies are needed to generate a new domestic application standard for ATⅢ supplementation therapy.

AntithrombinⅢ, DIC, ATⅢ activation, Sepsis, Septic shock

  • 1. [학술지] Kushimoto S / 2008 / Clinical course and outcome of disseminated intravascular coagulation diagnosed by Japanese Association for Acute Medicine criteria. Comparison between sepsis and trauma / Thromb Haemost / 100 (6) : 1099 ~ 6
  • 2. [학술지] Iba T / 2016 / Present and future of anticoagulant therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation : a perspective from Japan / Int J Hematol / 103 (3) : 253 ~ 3
  • 3. [학술지] Tagami T / 2014 / Antithrombin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation : an observational nationwide study / J Thromb Haemost / 12 (9) : 1470 ~ 9
  • 4. [학술지] Yamakawa K / 2016 / Benefit profile of anticoagulant therapy in sepsis : a nationwide multicentre registry in Japan / Crit Care / 20 (1) : 229
  • 5. [학술지] Warren BL / 2001 / High-dose antithrombin III in severe sepsis : a randomized controlled trial / Jama / 286 (15) : 1869 ~ 15
  • 6. [학술지] Kienast J / 2006 / Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without dissemi-nated intravascular coagulation / J Thromb Haemost / 4 (1) : 90 ~ 1
  • 7. [학술지] Umemura Y / 2016 / Efficacy and safety of anticoagulant therapy in three specific populations with sepsis : a meta-analysis of randomized controlled trials / J Thromb Haemost / 14 (3) : 518 ~ 3
  • 8. [학술지] Hayakawa M / 2018 / Optimal Antithrombin Activity Threshold for Initiating Antithrombin Supplementation in Patients With Sepsis-Induced Disseminated Intravascular Coagulation : A Multicenter Retrospective Observational Study / Clin Appl Thromb Hemost / 24 (6) : 874 ~ 6
  • 9. [학술지] 하상욱 / 2016 / Performance Evaluation of Five Different Disseminated Intravascular Coagulation (DIC) Diagnostic Criteria for Predicting Mortality in Patients with Complicated Sepsis / Journal of Korean Medical Science / 31 (11) : 1838 ~ 11 kci
  • 10. [학술지] Iba T / 2015 / The usefulness of antithrombin activity monitoring during antithrombin supplementation in patients with sepsis-associated disseminated intravascular coagulation / Thromb Res / 135 (5) : 897 ~ 5
  • 11. [학술지] Iba T / 2018 / A Proposal of the Modification of Japanese Society on Thrombosis and Hemostasis(JSTH)Disseminated Intravascular Coagulation(DIC)Diagnostic Criteria for Sepsis-Associated DIC / Clin Appl Thromb Hemost / 24 (3) : 439 ~ 3
  • 12. [학술지] 김지영 / 2007 / 패혈증 환자에서의 혈액응고계의 변화에 대한 고찰 / Annals of Laboratory Medicine / 27 (3) : 157 ~ 3 kci